How Pancrelipase Treats Pancreatic Insufficiency

Pancrelipase is a prescription medication made from pig pancreas that replaces the digestive enzymes your body cannot produce on its own. It contains three key enzymes: lipase (which breaks down fat), amylase (which breaks down starch), and protease (which breaks down protein).¹ People take it when their pancreas is damaged or missing, a condition broadly known as exocrine pancreatic insufficiency, and the drug is one of a very small number of treatments where “replacement therapy” truly means what it says: putting back what the body has lost.

Why Someone Would Need Pancrelipase

Your pancreas normally releases a cocktail of digestive enzymes into the small intestine every time you eat. When it can’t do that job, fat and other nutrients pass through your gut undigested. The medical term for this is exocrine pancreatic insufficiency (EPI), and its hallmark symptoms include greasy, foul-smelling stools (called steatorrhea), unintentional weight loss, bloating, and deficiencies in fat-soluble vitamins like A, D, E, and K.²

Chronic pancreatitis is the most common reason people develop EPI, but it is far from the only one. Cystic fibrosis damages the pancreas early in life. Pancreatic tumors and surgical removal of part or all of the pancreas are also frequent culprits.³ Less obviously, EPI can also develop in people with diabetes, celiac disease, inflammatory bowel disease, or simply advanced age, as well as after certain gastrointestinal surgeries that don’t directly involve the pancreas at all.⁴ That last category surprises a lot of people. You don’t necessarily need something “wrong” with your pancreas itself to end up unable to digest food properly.

How Doctors Diagnose the Problem

Before you start taking pancrelipase, a doctor needs to confirm that your pancreas actually isn’t producing enough enzymes. The most widely used initial test measures a protein called fecal elastase-1 in a stool sample. It’s practical because it requires just a single bowel movement, doesn’t need you to stop eating any particular foods beforehand, and can even be done while you’re already on enzyme therapy.⁵

A level below 100 micrograms per gram of stool is strong evidence of EPI. Between 100 and 200 is considered indeterminate, and above 200 is generally normal.⁶ A systematic review found the test picks up EPI with about 96% sensitivity overall, though it is less reliable in mild cases, where sensitivity drops to around 63%.⁷⁸ That’s worth keeping in mind: if your symptoms strongly suggest EPI but your fecal elastase comes back borderline, a negative result doesn’t necessarily rule it out.

One thing the American Gastroenterological Association specifically warns against is using a therapeutic trial of enzymes as a diagnostic test. In other words, “take these pills and see if you feel better” is not a reliable way to confirm EPI, because improvement in symptoms could come from a placebo effect or from addressing an unrelated issue.⁹

How the Drug Works and Why Formulation Matters

At its core, pancrelipase is straightforward: it puts pig-derived digestive enzymes into your gut to do the job your pancreas can’t. But making that work in practice is trickier than it sounds, because the enzymes have to survive your stomach acid long enough to reach the small intestine where digestion actually happens. Unprotected enzymes get destroyed at a pH of about 4 or below, which is well above the acidity of a typical stomach.¹⁰

Modern pancrelipase products solve this with enteric coating, a protective shell around tiny pellets (sometimes called microspheres or minimicrospheres) that resists stomach acid and dissolves only when the pH rises in the upper small intestine. The capsule you swallow breaks apart in the stomach, releasing hundreds of these coated pellets, which then empty gradually alongside your food. This timing matters: if the enzymes dump into the intestine long before the food arrives, or long after, you don’t get much benefit.

For people who still have symptoms despite taking their enzymes correctly, adding a proton pump inhibitor (a common acid-reducing medication) can help. By raising the stomach’s pH, the PPI protects more of the enzyme activity and allows the enteric coating to dissolve more predictably. Research has shown that this combination significantly improves fat digestion and reduces steatorrhea compared to enzymes alone.¹¹

How Well Pancrelipase Works

The central measure researchers use to gauge effectiveness is the coefficient of fat absorption (CFA), which tells you what percentage of the fat you eat actually gets absorbed rather than passing through. In a key double-blind trial of patients with EPI from chronic pancreatitis or pancreatic surgery, those on pancrelipase improved their CFA by about 32 percentage points on average, compared to roughly 9 percentage points with placebo.¹² In practical terms, that’s the difference between malabsorbing most of the fat in your diet and absorbing a healthy share of it.

Over longer periods, the benefits extend beyond lab values. A six-month open-label trial found that patients on pancrelipase gained an average of about 2.7 kilograms of body weight, had roughly one fewer bowel movement per day, and experienced improvements in abdominal pain, gas, and stool consistency.¹³ For someone who has been losing weight, dealing with urgent and unpredictable bowel habits, and avoiding social meals, those changes are life-altering.

Evidence-based reviews have concluded that delayed-release pancrelipase significantly improves both fat and nitrogen absorption along with clinical symptoms, without major safety concerns, making it a standard therapy for EPI.¹⁴

Pancrelipase in Cystic Fibrosis

Cystic fibrosis deserves its own discussion because it’s the condition most closely linked to lifelong pancrelipase use. Roughly 85% of people with CF develop EPI, often beginning in infancy. Enzyme therapy is started early and typically continues for life. Yet despite how universally it is prescribed, a Cochrane systematic review found that there isn’t strong evidence that any one pancrelipase formulation is better than another for the outcomes that matter most, like weight, height, or body mass index.¹⁵ That doesn’t mean the therapy isn’t effective; it means comparative data between brands is thin, and the best choice for any given patient often comes down to tolerability and practical preferences like capsule size.

What makes CF unique is the population: children, sometimes very young ones, who need enzyme dosing adjusted as they grow. Doses in CF are typically titrated based on lipase units per kilogram of body weight per meal, and getting the dose right is a constant balancing act between absorbing enough nutrition and avoiding the serious complications that come from taking too much.

Pancrelipase and Pancreatic Cancer

EPI is common in people with pancreatic cancer, whether or not they have had surgery. The tumor itself, or the chemotherapy used to treat it, can impair pancreatic function. Maintaining weight and nutritional status during cancer treatment is critical, so enzyme therapy often gets prescribed. The evidence here, however, is more mixed than in chronic pancreatitis.

A prospective cohort study comparing patients on pancrelipase to a historical group found that those receiving enzymes maintained their BMI better over time, though the improvement in serum albumin (a marker of nutritional status) did not reach statistical significance.¹⁶ A separate randomized trial, however, found no significant difference in BMI change at eight weeks between patients who received pancrelipase and those who did not. Median overall survival trended higher in the enzyme group (19 months versus 12 months), but this difference also did not reach statistical significance.¹⁷

The upshot for patients with pancreatic cancer is that enzyme therapy is unlikely to hurt and may help with nutrition, but the evidence for a strong survival or weight benefit in this population is still inconclusive. Many oncologists prescribe it anyway, reasoning that the potential upside outweighs the minimal risk.

Safety Concerns and Side Effects

For most people, pancrelipase is well tolerated. Common side effects tend to be gastrointestinal: nausea, cramping, diarrhea, or constipation. These are usually mild and often improve with dose adjustment. The more serious safety concerns are specifically about high doses and about specific populations.

The most alarming historical safety issue is fibrosing colonopathy, a condition where the wall of the colon thickens and narrows. It was identified in the 1990s almost exclusively in children with cystic fibrosis who were taking very high doses of pancreatic enzymes. A landmark study in the New England Journal of Medicine found that the risk climbed steeply with dose: children taking more than 50,000 lipase units per kilogram per day had a dramatically elevated risk compared to those on lower doses.¹⁸ This finding led to dosing guidelines that most CF centers now follow carefully, generally capping lipase at 10,000 units per kilogram per day or 2,500 units per kilogram per meal.

More recent surveillance data suggests that at currently recommended doses, fibrosing colonopathy is extremely rare. One large analysis found an incidence of roughly 0.024 confirmed cases per 1,000 person-years of enzyme use, and all confirmed cases occurred during active enzyme therapy.¹⁹ That is reassuringly low, but it underscores why dose limits exist and why clinicians take them seriously.

Another older but still relevant concern is hyperuricosuria, where high doses of pancreatic enzymes lead to excessive uric acid in the urine because the enzymes contain purines (building blocks of DNA). In reported pediatric cases, reducing the enzyme dose by a large margin brought uric acid levels back down.²⁰ This is mainly a consideration for patients already at risk of kidney stones or gout.

Practical Tips for Taking Pancrelipase

Getting the most out of pancrelipase involves more than just remembering to take it. A few practical points make a real difference in how well the drug works:

Timing: Take capsules at the beginning of a meal or snack, not after. The enzymes need to mix with food in the stomach so they empty into the small intestine together. If you take them on an empty stomach, the pellets may pass through before the food arrives.
Snacks count: Any food containing fat triggers the need for enzymes. Skipping doses with snacks is a common reason people still have symptoms despite taking their medication with main meals.
Don’t crush or chew: The enteric-coated pellets inside the capsule are designed to survive stomach acid. Crushing or chewing them destroys that protection and can also irritate the lining of your mouth.
Capsule opening: If you or your child can’t swallow the whole capsule, you can open it and sprinkle the pellets onto a small amount of acidic soft food like applesauce. The food must be acidic (pH below 4.5) so the enteric coating stays intact until the pellets reach the intestine. Swallow immediately without chewing.

For people who cannot swallow at all and rely on a feeding tube, the pellets can be mixed with acidic baby food and administered through the tube without losing their protective coating or enzyme activity, provided the tube is the right size. In vitro testing confirmed this works with several common gastrostomy tube brands at 16 French and larger.²¹ An alternative approach dissolves the capsule contents in a sodium bicarbonate solution, which strips the enteric coating and frees the enzymes into liquid form for tube delivery.²² Each method has trade-offs, and the choice often depends on the clinical setting and what equipment is available.

Supply Shortages and Cost

Because pancrelipase comes from pig pancreas tissue, it is subject to the same supply-chain vulnerabilities as any animal-derived product: disease outbreaks in pork herds, manufacturing disruptions, and raw material shortages. These aren’t hypothetical problems. An analysis of prescribing data in England documented a significant shortage of the most common formulation, Creon 25,000. During the shortage, prescriptions for lower-strength Creon 10,000 roughly tripled in secondary care, and an alternative product called Nutrizym more than doubled in primary care use.²³ Even with these substitutions, overall prescribing remained below predicted levels during the shortage, meaning some patients were likely undertreated.

Cost is another ongoing barrier. In the United States, pancrelipase products are brand-name drugs, and because the FDA required all manufacturers to go through a formal approval process starting in 2010, there are no true generics on the market. A month’s supply can run into hundreds of dollars without insurance. Patient assistance programs exist through the major manufacturers, but navigating them requires effort, and gaps in coverage are common during insurance transitions.

Manufacturing Safety and Quality Control

Since pancrelipase is derived from animal tissue, regulators require that the manufacturing process eliminate any risk of viral contamination. Validation studies have tested the final drying step of production against a panel of animal viruses, including pseudorabies virus, encephalomyocarditis virus, bovine viral diarrhea virus, and porcine parvovirus. The process achieved substantial virus reduction across all four, with no detectable viral particles remaining after treatment.²⁴ This testing is not optional; it’s a regulatory requirement and one of the reasons pancrelipase products are expensive to produce.

Non-Porcine Alternatives on the Horizon

The reliance on pig pancreas has long been a weak point of enzyme replacement therapy, whether you’re concerned about supply chain fragility, religious or dietary restrictions around pork, or simply the environmental footprint of sourcing from animal agriculture. Several groups are developing alternatives, and the early results are promising.

ANG003 is a non-porcine enzyme product that has been tested in people with cystic fibrosis. In a clinical trial, it significantly improved the absorption of both omega-3 fatty acids (DHA and EPA) and total dietary fat at its higher doses, with only mild and temporary side effects and no serious adverse events.²⁵

A separate approach uses an engineered microbial lipase, essentially a lab-designed enzyme produced by microorganisms rather than harvested from animals. In animal models, this lipase achieved comparable fat absorption to porcine-derived therapy at roughly one-tenth the dose by mass, and it did not require enteric coating because it was engineered to withstand stomach acid. A small early-phase human trial showed improved fat absorption and a favorable safety profile.²⁶ If this kind of product reaches the market, it could simplify manufacturing, reduce costs, and eliminate the enteric-coating step that makes current products finicky to administer through feeding tubes or for very young children.

Neither product is commercially available yet, and the gap between promising early trials and an approved drug on pharmacy shelves is famously wide. But the direction is clear: the field is actively trying to move beyond the pig-pancreas model that has defined enzyme replacement therapy for over a century.